diagnosed with the 2003 Rotterdam criteria [4, 5] .
Plasminogen activator inhibitor-1 (PAI-1) is a key regulator of fibrinolysis and inhibits the activation of plasminogen to plasmin by both the tissue-type and the urokinase-type plasminogen activators [7] . In addition, PAI-1 is a marker of IR and plasma PAI-1 antigen levels and activity are frequently elevated in insulin resistant states, including abdominal obesity, the metabolic syndrome and type 2 diabetes mellitus (T2DM) [7] . Several prospective studies in the general population suggested that elevated PAI-1 levels are associated with increased risk for T2DM [8, 9] .
Given the increased prevalence of IR in women with PCOS and the association between circulating PAI-1 levels and IR, several studies assessed plasma PAI-1 levels in PCOS [10] [11] [12] [13] [14] [15] [16] . Most, but not all, reported elevated plasma PAI-1 levels in women with PCOS [10] [11] [12] [13] [14] [15] [16] . However, existing studies are relatively small and none of them compared plasma PAI-1 levels between the different phenotypes of the syndrome level of the widest diameter around the buttocks. The W/H was calculated by dividing W by H.
Baseline blood samples were collected between days 3 and 7 of the menstrual cycle in the control group and between 3 to 7 days after a spontaneous bleeding episode in patients with PCOS, after an overnight fast. The circulating levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), testosterone (T), Δ 4 -androstenedione (Δ 4 -A), dehydroepiandrosterone sulfate (DHEA-S), 17α-OHP, sex hormone-binding globulin (SHBG), glucose, insulin, thyroid stimulating hormone (TSH) and free thyroxin (FT4) were measured. Immediately after the baseline blood sampling an oral glucose tolerance test (OGTT) was performed; 75 g of glucose were administered orally and serum glucose levels were determined after 30, 60, 90 and 120 min. At the same day transvaginal ultrasonography was performed and the volume of each ovary was determined, as well as the number of follicles in each ovary.
Patients with PCOS and controls were divided according to BMI in normal weight (BMI < 25 kg/m 2 ; n = 100 and n = 25, respectively) and overweight/obese (ΒΜΙ > 25 kg/m 2 ; n = 99 and n = 25, respectively; Fig. 1 ). Normal weight and overweight/obese patients with PCOS were further divided in patients who were diagnosed with PCOS according to the 1990 criteria (n = 50 and n = 49, respectively) [2] and in patients with the additional PCOS phenotypes introduced by the 2003 criteria (n = 50 and n = 50, respectively; Fig. 1 ) [3] . Patients diagnosed with PCOS according to the 1990 criteria had oligo-or anovulation (<8 spontaneous hemorrhagic episodes/yr), biochemical hyperandrogenemia (early follicular phase T levels > 60 ng/dL, corresponding to the mean±2 SD of 200 control subjects measured in our laboratory), and polycystic ovaries on ultrasound (≥ 12 follicles with a diameter of 2-9 mm in at least 1 ovary and/or ovarian volume >10cm
3 ) [phenotype 1 ("severe PCOS")] or normal sonographic appearance of the ovaries (phenotype 2). Patients with the additional PCOS phenotypes introduced by the 2003 criteria had hyperandrogenemia and polycystic ovaries without oligo-or anovulation [phenotype 3 ("ovulatory" PCOS)] or had oligo-or anovulation and polycystic ovaries, without biochemical hyperandrogenemia or clinical manifestations of hyperandrogenemia [phenotype 4 ("mild" PCOS)]. [10] [11] [12] [13] [14] [15] [16] . Accordingly, the aim of the present study was to evaluate plasma PAI-1 levels in a large cohort of women with PCOS and to assess these levels in women with different levels of adiposity and different phenotypes of PCOS.
patients and Methods

Patients
We 2 ) (control group). All women with PCOS were outpatients at the Gynecological Endocrinology Infirmary of the Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Greece. Women of the control group were healthy volunteers with normal ovulating cycles (28±2 days, blood progesterone levels > 10 ng/mL in two consecutive cycles), no signs of hyperandrogenism and normal sonographic appearance of the ovaries.
Diagnosis of PCOS was based on the revised criteria of Rotterdam (see study protocol) [3] . None of the women studied had galactorrhea or any endocrine or systemic disease that could possibly affect reproductive physiology. No woman reported use during the last semester of any medication that could interfere with the normal function of the hypothalamic-pituitary-gonadal axis. When basic 17α-hydroxyprogesterone (17α-OHP) levels were > 1.5ng/mL, the Synacthen test (0.25 mg/ mL; Novartis Pharma S.A., Rueil-Malmaison, France) was performed to rule out congenital adrenal hyperplasia. Other causes of hyperandrogenemia, including prolactinoma, Cushing's syndrome and androgen secreting tumors were also excluded.
Informed consent was obtained from all women, and the study was approved by the institutional review board. The study met the requirements of the 1975 Helsinki guidelines.
Study protocol
In all women, body weight, height, waist circumference (W) and hip circumference (H) were measured. Body weight was measured with analog scales and in light clothing; height was measured barefoot with a stadiometer. The BMI was calculated by dividing weight (in kg) by height squared (in m) to assess obesity. The W was obtained as the smallest circumference at the level of the umbilicus and the H was measured at the with the Kolmogorov-Smirnov test, log transformation was performed. Differences between groups were assessed with one-way analysis of variance with the Holm-Sidak method for multiple comparison testing. Independent correlations between plasma PAI-1 levels and other parameters were assessed with stepwise linear regression analysis including parameters that were significantly correlated with plasma PAI-1 levels in univariate analysis. In all cases, a p value < 0.05 was considered significant.
Results
Characteristics of the total study population are shown in Table 1 . Circulating androgens were higher in women with PCOS regardless of phenotype than in controls. Women with phenotypes 1 and 2 of PCOS had higher plasma T, Δ 4 -A and DHEA-S levels and FAI than women with phenotypes 3 and 4 (p < 0.001 for all comparisons). In addition, women with phenotypes 1 and 2 had higher plasma LH and insulin levels and lower glucose/insulin and QUICKI than controls whereas women with phenotypes 3 and 4 did not differ from controls in these parameters. Plasma PAI-1 levels were higher in women with phenotypes 1 and 2 and in women with phenotypes 3 and 4 of PCOS compared with controls (p < 0.001 for both comparisons) but did not differ between women with phenotypes 1 and 2 and women with phenotypes 3 and 4 of PCOS (Fig. 2) .
Characteristics of normal weight women are shown in Table 2 . Circulating androgens were higher in women with PCOS regardless of phenotype than in
Methods
Plasma glucose, insulin, FSH, LH, PRL, androgens, 17α-OHP, TSH and FT4 concentrations were measured as previously described [17] . Plasma SHBG levels were determined with an immunoradiometric assay (SHBG Immunoradiometric assay test, Diagnostics Systems Laboratories, Webster, TX, USA). Plasma PAI-1 levels were determined with an enzyme-linked immunosorbent assay (Bender MedSystems GmbH, Vienna, Austria). The intra-and inter-assay coefficients of variation were 4.7 and 5.0%, respectively. Free androgen index (FAI) was determined as follows: FAI = T (nmol/L) x 100 / SHBG (nmol/L) [18] . The homeostasis model assessment of IR (HOMA-IR) index was calculated as follows: HOMA-IR = fasting insulin (mIU/L) x glucose (mg/dL) / 405 [19] . The quantitative insulin sensitivity check index (QUICKI) was calculated according to the following formula: QUICKI = 1 / [log Insulin (mIU/L) + log Glucose (mg/dL)] [20] .
Transvaginal ultrasonography
Transvaginal ultrasonography was performed by an experienced operator in all women. Ovarian volume was calculated as follows: Ovarian volume = (π/6) x ovarian length x ovarian height x ovarian width.
Statistical analysis
Data analysis was performed with the statistical package SPSS (version 17.0; SPSS Inc., Chicago, IL). Data are reported as mean±SD. Because plasma PAI-1 levels did not follow normal distribution as assessed controls. Women with phenotypes 1 and 2 of PCOS had higher plasma T, Δ 4 -A and DHEA-S levels and FAI and lower plasma FSH levels than women with phenotypes 3 and 4. In addition, women with phenotypes 1 and 2 had higher plasma 17α-OHP levels and lower plasma SHBG levels and area under the OGTT curve (AUC OGTT) than controls whereas women with phenotypes 3 and 4 did not differ from controls in these parameters. Plasma PAI-1 levels did not differ between women with PCOS (regardless of phenotype) and controls or between women with phenotypes 1 and 2 and women with phenotypes 3 and 4 of PCOS (Fig. 2) .
Characteristics of overweight/obese women are shown in Table 3 . Circulating androgens were higher in women with PCOS regardless of phenotype than in controls. Women with phenotypes 1 and 2 of PCOS had higher W, W/H, plasma T and DHEA-S levels and In normal weight controls, in univariate analysis, plasma PAI-1 levels correlated with the mean number of follicles in the two ovaries (r = 0.429, p = 0.032). In overweight/obese controls, in univariate analysis, plasma PAI-1 levels correlated with the FAI (r = 0.592, p = 0.002) and plasma SHBG levels (r = -0.566, p = 0.003). In stepwise linear regression analysis, plasma PAI-1 levels were independently correlated with the FAI (p = 0.002).
FAI than women with phenotypes 3 and 4. In addition, women with phenotypes 1 and 2 had higher plasma insulin levels and lower glucose/insulin and QUICKI than controls whereas women with phenotypes 3 and 4 did not differ from controls in these parameters. Plasma PAI-1 levels were higher in women with phenotypes 1 and 2 and in women with phenotypes 3 and 4 of PCOS compared with controls (p < 0.001 and p = 0.004, respectively) but did not differ between women with phenotypes 1 and 2 and women with phenotypes 3 and 4 of PCOS (Fig. 2) . The difference in plasma PAI-1 levels between women with phenotypes 1 and 2 of PCOS and controls persisted after adjustment for the higher BMI in the former group (adjusted p = 0.010).
In normal weight women with PCOS, in univariate analysis, plasma PAI-1 levels correlated with plasma 17α-OHP levels (r = -0.222, p = 0.027). In overweight/obese women with PCOS, in univariate analysis, plasma PAI-1 levels positively correlated with BMI did not correlate with indices of IR.
In contrast to normal weight subjects, overweight/ obese patients with PCOS had higher PAI-1 levels than BMI-matched controls, a finding that concurs with most previous studies [13] [14] [15] [16] 23] . However, plasma PAI-1 levels did not correlate with markers of IR in overweight/obese women with PCOS in our study and this is in contrast to previous reports [13, 14, 24, 25] . Therefore, our findings do not support a role for IR in the increase of PAI-1 levels in overweight/obese patients with PCOS. An alternative explanation for the lack of relationship between PAI-1 levels and IR in our study might be the relatively low sensitivity of the markers we used to assess IR (i.e. serum insulin levels, glucose/insulin, AUC OGTT, HOMA-IR and QUICKI) [26] . Indeed, in women with PCOS, neither HOMA-IR nor QUICKI correlates with IR measured with the euglycemic hyperinsulinemic clamp, i.e. the gold standard for evaluating IR [26, 27] . However, it is difficult to perform euglycemic hyperinsulinemic
Discussion
This is the largest study that assessed circulating PAI-1 levels in PCOS and the first that compared PAI-1 levels between the different phenotypes of the syndrome. Our results suggest that plasma PAI-1 levels are elevated in overweight/obese women with PCOS but not in normal weight women compared with BMImatched controls and that PAI-1 levels are similar in the different phenotypes of the syndrome.
In agreement with our findings, previous smaller studies did not identify any difference in circulating PAI-1 levels between normal weight women with PCOS and BMI-matched healthy controls [10] [11] [12] . In contrast, others reported higher PAI-1 levels in normal weight women with PCOS and a correlation between PAI-1 levels and both serum insulin levels and the HOMA-IR index [13, 21, 22] . However, our findings do not suggest that IR modulates PAI-1 levels in normal weight women with PCOS because PAI-1 levels drogenemia in the regulation of PAI-1 levels in PCOS. Given the association between IR and hyperandrogenemia [1] , it is possible that the correlation between circulating androgens and PAI-1 levels in previous studies [12, 16, 28, 29] might reflect the higher IR in women with more severe hyperandrogenemia.
Our findings that PAI-1 levels are elevated in overweight/obese women with PCOS and that this increase might be partly due to IR have several potential implications. First, women with PCOS appear to have increased risk for developing T2DM and this is partly due to the high prevalence of IR in this syndrome [30, 31] . Accordingly, PAI-1 might represent a marker of risk for T2DM in PCOS. Second, recent data suggest that women with PCOS have greater risk for cardiovascular events [31, 32] and increased PAI-1 levels predict cardiovascular events in some, but not all, studies in the general population [33] [34] [35] . Therefore, PAI-1 levels might represent a useful tool for cardiovascular risk stratification in women with PCOS. Third, elevated PAI-1 levels in PCOS might play a role in the anovulatory infertility of these women through the regulation of proteolysis during ovarian follicle growth [24, 36] . Therefore, targeting IR in women with PCOS might also result in a decrease in PAI-1 levels and this might translate into lower risk for T2DM and cardiovascular events as well as restoration of ovulation and improvement in conception rates. Indeed, both weight loss and metformin lowered PAI-1 levels in obese women with PCOS and this decrease correlated with the reduction in serum insulin levels [14, 15, 24, 25] .
In conclusion, our study suggests that PAI-1 levels are elevated in overweight/obese women with PCOS but not in normal weight women with this syndrome. Plasma PAI-1 antigen levels do not differ between the phenotypes of PCOS. It remains to be established whether PAI-1 might be useful in the prediction of T2DM and cardiovascular events in PCOS and whether strategies aiming at lowering PAI-1 levels will also reduce the risk for these complications.
clamp in large populations.
Plasma PAI-1 levels did not differ between women with PCOS diagnosed with the 1990 NIH criteria and women diagnosed with the additional 2003 Rotterdam criteria in either normal weight or overweight/obese subjects. In a recent study that included both normal weight and overweight/obese women with PCOS (mean BMI 27.7±7.0 kg/m 2 ), PAI-1 activity was higher in women with PCOS diagnosed with the 1990 criteria than in controls whereas women with PCOS with isolated hyperandrogenism or isolated oligo-or anovulation had comparable PAI-1 activity with controls [28] . However, women with PCOS diagnosed with the 1990 criteria were not compared with those diagnosed with the additional 2003 criteria. In addition, normal weight and overweight/obese women with PCOS were not analyzed separately [28] . In our study, markers of IR did not differ between the phenotypes of PCOS and this might partly explain the similar PAI-1 levels. There are conflicting data on the differences in metabolic characteristics between PCOS phenotypes and more studies are needed in this field [4, 5] .
In previous studies that included both normal weight and overweight/obese women with PCOS, PAI-1 antigen levels positively correlated with serum T levels and negatively with serum SHBG levels [28, 29] . In other studies, PAI-1 levels were higher in obese women with PCOS only when biochemical hyperandrogenemia was present [12] and the difference in PAI-1 levels between overweight/obese women with PCOS and controls disappeared after adjustment for androgen levels [16] . In contrast, in our study, there was no correlation between PAI-1 levels and circulating androgens in either normal weight or overweight/obese women with PCOS. Moreover, PAI-1 levels did not differ between normal weight women with PCOS and controls or between women with phenotypes 1 and 2 and women with phenotypes 3 and 4 despite a significant difference in androgen levels between these groups. Therefore, our findings argue against an important role of hyperan-
